Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
CHR-3996 is one of a new class of anti-cancer agents - histone deacetylase inhibitors (HDACi)
- that has exhibited pleiotropic activity both in vitro and in vivo against a range of human
cancer cells. Regulation of the acetylation of both histone and non-histone proteins by
histone deacetylase enzymes is one of the key mechanisms involved in epigenetic control of
gene expression. HDACi have demonstrated activity in both in vitro cytotoxicity, and in vivo
tumour xenograft studies